Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Lancet Oncol. 2014 Nov 12;15(13):1481–1492. doi: 10.1016/S1470-2045(14)70486-3

Figure 3. Post-relapse survival curves.

Figure 3

(A) Unadjusted Kaplan-Meier plot of post-relapse survival in patients receiving adjuvant capecitabine plus oxaliplatin (XELOX) or leucovorin and fluorouracil plus oxaliplatin (FOLFOX) compared with those receiving leucovorin and fluorouracil alone. (B) Adjusted post-relapse survival in patients receiving adjuvant capecitabine plus oxaliplatin (XELOX) or leucovorin and fluorouracil plus oxaliplatin (FOLFOX), compared with those receiving leucovorin and fluorouracil alone (adjusted for sex, age, tumour [T] stage, and nodal [N] stage), generated by the average covariate method. (C) Adjusted post-relapse survival in patients receiving adjuvant capecitabine plus oxaliplatin (XELOX) or leucovorin and fluorouracil plus oxaliplatin (FOLFOX), compared with those receiving leucovorin and fluorouracil alone (adjusted for sex, age, T stage, and N stage), generated by the corrected group prognosis method. (D) Unadjusted Kaplan-Meier plot of post-relapse survival in patients receiving adjuvant capecitabine plus oxaliplatin (XELOX) or leucovorin and fluorouracil plus oxaliplatin (FOLFOX) compared with those receiving leucovorin and fluorouracil alone, by nodal stage. HR=hazard ratio. XELOX=capecitabine plus oxaliplatin. FOLFOX=leucovorin and fluorouracil plus oxaliplatin. N=nodal stage. Please note that figures without numbers at risk display adjusted survival curves derived from a Cox proportional hazards regression model (rather than Kaplan–Meier survival analysis); hence, those data are not directly used.